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Abstract: Herein we describe the synthesis and in vitro biological evaluation of thirteen new, racemic,
diversely functionalized imidazo pyranotacrines as non-hepatotoxic, multipotent tacrine analogues.
Among these compounds, 1-(5-amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-6,7,8,9-tetrahydro-4H-
pyrano[2,3-b]quinolin-3-yl)ethan-1-one (4) is non-hepatotoxic (cell viability assay on HepG2 cells),
a selective but moderately potent EeAChE inhibitor (IC50 = 38.7 ˘ 1.7 µM), and a very potent
antioxidant agent on the basis of the ORAC test (2.31 ˘ 0.29 µmol¨Trolox/µmol compound).
Keywords: tacrine analogues; hepatotoxicity; cholinesterase inhibitors; antioxidant activity; ORAC;
Alzheimer1s disease
1. Introduction
Alzheimer1s disease (AD) is an age-related neurodegenerative disorder whose prevalence is
expected to rise significantly in the next decades as the average age of the population increases [1].
Worldwide, around 40 million people suffer from AD [2], which is characterized by a progressive
memory loss, a decline in language skills and motor capabilities along with other cognitive
impairments [3]. Although the etiology of AD is not completely known, common hallmarks such as
β-amyloid (Aβ) deposits [4], τ-protein aggregation [5] and oxidative stress [6] play key roles in the
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physiopathology of the disease [7]. In addition, the selective loss of cholinergic neurons in AD results
in a deficit of the neurotransmitter acetylcholine (ACh) in specific brain regions that mediate learning
and memory [8]. Alterations in the serotoninergic and dopaminergic systems are also thought to be
responsible for the behavioral disturbances observed in AD patients [9]. At present, there are three
FDA-approved drugs (donepezil, galantamine and rivastigmine) [10] that ameliorate AD symptoms
by inhibiting acetylcholinesterase (AChE), the enzyme responsible for the hydrolysis of ACh, and by
rising the ACh content in the synapsis [11]. Apart from the beneficial palliative properties of AChE
inhibitors (AChEI) in AD, cholinergic drugs have shown little efficacy to prevent the progression
of the disease. Consequently, nowadays there is no efficient therapy to cure, stop or even slow the
progression of the disease. Hence, effective therapeutics are urgently sought [12].
The failure to find such a drug or treatment is possibly due to the multifactorial nature of AD.
Thus, single drugs acting on specific targets to produce the expected clinical effects might not be
effective in interfering with the complex nature of AD. This is the reason why the multi-target-directed
ligand (MTDL) approach [13] has received an increasing attention by many research groups that have
developed a variety of compounds binding very diverse biochemical targets [14].
Among the AChEIs investigated in the search for a pharmacological treatment for AD, the case
of tacrine is particularly relevant [15]. Tacrine (Figure 1) is one of the strongest butyrylcholinesterase
(BuChE) inhibitors known to date [16]. This drug, which was withdrawn from the clinical use for
AD treatment because of significant liver toxicity [17], has been largely stigmatized instead of being
further developed looking for other non-toxic tacrines retaining valuable anti-ChE properties [18].
In this context, we have reconsidered tacrine as a starting scaffold in the design of new Multipotent
Non-Toxic Tacrines (MNTTs), [19] by incorporating other pharmacophoric groups capable of binding
or inhibiting other molecular targets involved in the onset and/or progression of the disease. With
this idea in mind, since 1997 we developed different types of structurally simple and easily available
MNTTs [20].
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Figure 1. General structure of tacrine, 4H-pyrans (I), and the new racemic imidazopyranotacrines (II). 
Thus, expanding our contribution in this area, in this work we report the synthesis of a number of 
new imidazopyranotacrines (II), a new family of tacrine derivatives resulting from the substitution of the 
ring A in tacrine by the 4H-pyrano (I) heterocyclic motif (Figure 1). In this case, we have incorporated, 
and at the same position, instead of a substituted phenyl ring [21], or a five- (furan [22], thiophen [22], 
pyrrole [22]) or six-membered heterocyclic ring system [23], the five-membered 1-methyl-1H-imidazol- 
2-yl motif, in order to improve previous biological results and gain new insights on the structure-activity 
relationship (SAR) of pyranotacrines. The imizadole ring is a privileged heterocyclic ring system [24] 
which is present in a number of interesting biologically active molecules such as saripidem, necopidem 
or zolpidem [25]. This choice was also favored by the ready availability of the imidazole substituted 
starting derivatives. 
Thus, in this work, we describe the synthesis and biological evaluation of the new 
imidazopyranotacrines 1–13 (Figure 2), the inhibition of AChE and BuChE enzymes, the antioxidant 
activities (ORAC-FL method), as well as the evaluation of their hepatotoxicity on HepG2 cells. As a 
result, we have identified racemic 1-(5-amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-6,7,8,9-tetrahydro- 
4H-pyrano[2,3-b]quinolin-3-yl)ethan-1-one (4) (Figure 2) as a non-hepatotoxic compound on HepG2 
cells, endowed with selective but moderate inhibitory activity against AChE from Electrophorus electricus 
(EeAChE), and very potent antioxidant activity. 
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Thus, expanding our contribution in this area, in this work we report the synthesis of a number
of new imidazopyranotacrines (II), a new family of tacrine derivatives resulting from the substitution
of the ring A in tacrine by the 4H-pyrano (I) heterocyclic motif (Figure 1). In this case, we have
incorporated, and at the same position, instead of a substituted phenyl ring [21], or a five- (furan [22],
thiophen [22], pyrrole [22]) or six-membered heterocyclic ring system [23], the five-membered
1-methyl-1H-imidazol-2-yl motif, in order to improve previous biological results and gain new insights
on the structure-activity relationship (SAR) of pyranotacrines. The imizadole ring is a privileged
heterocyclic ring system [24] which is present in a number of interesting biologically active molecules
such as saripidem, necopidem or zolpidem [25]. This choice was also favored by the ready availability
of the imidazole substituted starting derivatives.
Thus, in this work, we describe the synthesis and biological evaluation of the new
imidazopyranotacrines 1–13 (Figure 2), the inhibition of AChE and BuChE enzymes, the antioxidant
activities (ORAC-FL method), as well as the evaluation of their hepatotoxicity on HepG2 cells. As
a result, we have identified racemic 1-(5-amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-6,7,8,9-
tetrahydro-4H-pyrano[2,3-b]quinolin-3-yl)ethan-1-one (4) (Figure 2) as a non-hepatotoxic compound
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Figure 2. Structures of the imidazopyranotacrines 1–13.
2. Results and Discussion
2.1. Chemistry
The synthesis of racemic imidazopyranotacrine 1–13 has been arried out by Friedlä der-type
reactions [26], by treating readily available 4H-pyrans with commercial cycloalk ones, under standard
reaction conditions, and in good chemical yields. Cyclopentanone, cyclohexanone and cycloheptanone
were chosen in order to evaluate the effect of the size of the cycloalkyl ring on the biological activity
of the new pyranotacrines (Scheme 1). Starting from 1-methyl-1H-imidazole-2-carbaldehyde (14),
we synthesized 2-(1-methyl-1H-imidazol-2yl)methylene)malononitrile (15), whose reaction with
the appropriate 1,3-dicarbonylic compound or naphthol derivative, gave the key 4H-pyrans. For
the synthesis of pyranotacrines 1–3, we have used ethyl acetoacetate as starting material, thus
leading to imidazopyranotacrines bearing a methyl and ethoxycarbonyl substituents at C-2 and C-3,
respectively. Similarly, for the synthesis of the pyranotacri es 4 and 5 or 6, we used 2,4-pentandione,
and 5,5-dimethylcyclo exane-1,3-dione, respective y. Finally, for the synth sis of the rem ining
pyrano-tacrines 19–21 we have prepared some conveniently key functionalized 4H-pyrans from
1-naphthol, 2-naphthol, and 8-hydroxyquinoline. All new compounds showed excellent analytical and
spectroscopic data, in good agreement with their structures.
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Scheme 1. Synthesis of the imidazopyranotacrines 1–13. Reagents and conditions: (a) Malononitrile, 
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2,4-dione, piperidine, ethanol, rt (90%); (e) 5,5-dimethylcyclohexane-1,3-dione, piperidine, ethanol, rt 
(69%); (f) 2-naphthol, piperidine, ethanol, rt (72%); (g) 1-naphthol, piperidine, ethanol, rt (75%); (h) 
8-hydroxyquinoline, piperidine, ethanol, rt (47%). 
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2.2.1. Inhibition of the Cholinesterase Enzymes and Kinetic Analysis 
First of all, we addressed the capacity of imidazopyranotacrines 1–13 to inhibit EeAChE and 
serum horse BuChE (eqBuChE) by using Ellman′s assay [27], and tacrine as reference compound for 
comparative purposes [28]. 
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10, 2 and 1. The three most potent EeAChEIs among the imidazopyranotacrines (i.e., 8, 7 and 10) bear a 
naphthol ring fused to the central 4H-pyran motif. Furthermore, the 2-naphthol derivatives (7, 8) 
were more potent than the 1-naphthol ones (10, 11). The 2-naphthol derivative bearing a cyclohexane 
ring (8) is more potent than the analogues bearing a cyclopentane motif (7) or a cycloheptane motif 
(9). Note that the incorporation of a heterocyclic nitrogen in the 1-naphthol compounds (compare 
compound 11 with 13) significantly potentiates the inhibition of EeAChE, affording additional 
capacity for the inhibition of eqBuChE. For the other imidazopyranotacrines, it is clear that those 
bearing an ethoxycarbonyl moiety and a methyl group at C3 and C2, respectively, in the 4H-pyran 
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imidazopyranotacrines 1 and 2, differing only in the size of the cycloalkyl ring, are almost equipotent 
EeAChEIs, while 3, bearing a cycloheptane ring, is two orders of magnitude less active. Finally, 
regarding eqBuChE inhibition, imidazopyranotacrines 1–13 were very weak BuChEIs. Because of the 
Scheme 1. Synthesis of the imidazopyranotacrines 1–13. Reagents and conditions: (a) Malononitrile,
piperidine, ethanol, rt (93%); (b) ethyl 3-oxobutanoate, piperidine, ethanol, rt (92%); (c) cyclopentanone
(n = 0), cyclohexanone (n = 1), cycloheptanone (n = 2), AlCl3, 1,2-dichloroethane, reflux; (d)
pentane-2,4-dione, piperidine, ethanol, rt (90%); (e) 5,5-dimethylcyclohexane-1,3-dione, piperidine,
ethanol, rt (69%); (f) 2-naphthol, piperidine, ethanol, rt (72%); (g) 1-naphthol, piperidine, ethanol, rt
(75%); (h) 8-hydroxyquinoline, piperidine, ethanol, rt (47%).
2.2. Biological Assays
2.2.1. Inhibition of the Cholinesterase Enzymes and Kinetic Analysis
First of all, we addressed the capacity of imidazopyranotacrines 1–13 to inhibit EeAChE and
serum horse BuChE (eqBuChE) by using Ellman1s assay [27], and tacrine as reference compound
for comparative purposes [28].
As shown in Table 1, racemic imidazopyranotacrines 1–13 were very modest EeAChE inhibitors with
potencies in the micromolar range, resulting from two to three orders of magnitude less active than the
reference compound tacrine. On the other hand, all derivatives acted as highly selective AChEI, as
no or very moderate inhibition f eqBuChE activity was observed. The mo t potent EeAChEI w s the
imidazopyranotacrine 8 (IC50 = 6.73 ˘ 0.52 µM), followed, in decreasing order of activity, by 7, 10, 2 and
1. The three most potent EeAChEIs among the imidazopyranotacrines (i.e., 8, 7 and 10) bear a naphthol
ring fused to the central 4H-pyran motif. Furthermore, the 2-naphthol derivatives (7, 8) were more
potent than the 1-naphthol ones (10, 11). The 2-naphthol derivative bearing a cyclohexane ring (8) is
more potent than the analogues bearing a cyclopentane motif (7) or a cycloheptane motif (9). Note that
the incorporation of a heterocyclic nitrogen in the 1-naphthol compounds (compare compound 11 with
13) significantly potentiates the inhibition of EeAChE, affording additional capacity for the inhibition
of eqBuChE. For the other imidazopyranotacrines, it is clear that thos bearing an ethoxycarbonyl moiety
and a ethyl group at C3 C2, r spectively, in the 4H-pyran c re (1, 2) are more potent tha those
bearing a fused 3,3-dimethylcyclohexan-1-one (6, 5) or an acetyl and a methyl group (4) at C3 and
C2, respectively, in the 4H-pyran core. Note also that imidazopyranotacrines 1 and 2, differing only in
the size of the cycloalkyl ring, are almost equipotent EeAChEIs, while 3, bearing a cycloheptane ring,
is two orders of magnitude less active. Finally, regarding eqBuChE inhibition, imidazopyranotacrines
1–13 were very weak BuChEIs. Because of the weak inhibitory activity, high concentrations were
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required for the determination of the IC50 values, exceeding the solubility of some compounds. Thus,
imidazopyranotacrines 1–13 were screened at a single concentration, namely 10 µM, giving percentages
of inhibition between 12.9 and 75.7 (Table 1).
Table 1. Inhibitory potencies, expressed as IC50 values (µM), for the inhibition of EeAChE and eqBuChE,
and antioxidant power of imidazopyranotacrines 1–13.
Compound EeAChE a IC50 Values (µM) eqBuChE b % Inhibition at 10 µM ORAC d
1 12.9 ˘ 0.3 25.6 ˘ 0.7 0.34 ˘ 0.03
2 11.5 ˘ 0.4 34.0 ˘ 0.5 1.79 ˘ 0.17
3 432 ˘ 84 32.2 ˘ 0.9 1.99 ˘ 0.23
4 38.7 ˘ 1.7 24.9 ˘ 0.9 2.31 ˘ 0.29
5 158 ˘ 33 12.9 ˘ 0.5 1.70 ˘ 0.33
6 37.8 ˘ 1.2 33.5 ˘ 1.7 2.34 ˘ 0.31
7 8.41 ˘ 0.14 50.5 ˘ 7.3 1.47 ˘ 0.13
8 6.73 ˘ 0.52 51.6 ˘ 0.6 1.88 ˘ 0.01
9 na 15.1 ˘ 4.7 1.35 ˘ 0.13
10 10.7 ˘ 0.2 25.0 ˘ 0.2 2.75 ˘ 0.09
11 na 20.3 ˘ 3.7 2.33 ˘ 0.13
12 15.3 ˘ 0.6 27.5 ˘ 1.1 1.88 ˘ 0.07
13 30.0 ˘ 2.0 75.7 ˘ 2.3 2.25 ˘ 0.29
Tacrine 0.0898 ˘ 0.0022 0.005 ˘ 0.001 a,c 0.20 ˘ 0.04 [28]
a Each IC50 value is the mean ˘ SEM of at least two independent experiments each performed in triplicate.
b % inhibition at 10 µM is the mean ˘ SEM of at least three independent experiments. c IC50 value of tacrine
was given. d Data expressed as µmol Trolox/µmol compound. na: not significantly active (% inhibition lower
than 15%) when tested at the highest concentration (solubility limit), namely 15 µM and 25 µM for 9 and
11, respectively.
The mechanism of inhibition of EeAChE by the most potent AChEI, imidazopyranotacrine 8, was
investigated by building Lineweaver-Burk double reciprocal plots at increasing concentrations of
inhibitor and substrate (acetylthiocholine). Analysis of the Lineweaver-Burk reciprocal plots (Figure 3A)
showed that Km appeared unaltered while Vmax decreased at increasing concentrations of the
inhibitor. This pattern indicated that 8 acts as a non-competitive enzyme inhibitor. The non-competitive
mechanism of action was confirmed by building the Cornish-Bowden plot (Figure 3B). Replots of the
substrate/velocity versus the concentration of compound 8 provided an estimate of the non-competitive
inhibition constant [29], which resulted equal to 4.10 µM. The non-competitive mechanism of action
was confirmed by computational chemistry by performing the docking analysis of both enantiomers
of compound 8 on AChE (see Supplementary Materials).
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was confirmed by computational chemistry by performing the docking analysis of both enantiomers 
of compound 8 on AChE (see Supplementary Materials). 
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Figure 3. (A) Lineweaver-Burk plot and (B) Cornish-Bowden plot both illustrating non-competitive 
inhibition of EeAChE by compound 8. The intersection point in Cornish-Bowden plot gives an estimate 
of the inhibition constant. Lines were derived from a weighted least-squares analysis of data. ATCh = 
acetylthiocholine (substrate). 
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Figure 3. (A) Lineweaver-Burk plot and (B) Cornish-Bowden plot both illustrating non-competitive
inhibition of EeAChE by compound 8. The intersection point in Cornish-Bowden plot gives an estimate
of the inhibition constant. Lines were derived from a weighted least-squares analysis of data. ATCh =
acetylthiocholine (substrate).
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2.2.2. Antioxidant Power
The antioxidant power of the imidazopyranotacrines 1–13 was determined by the oxygen radical
absorbance capacity by fluorescence (ORAC-FL) method [30] using fluorescein as fluorescent probe
and Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) as a reference compound. Results
are expressed as Trolox equivalents (µmol Trolox per µmol test compound). As shown in Table 1,
all the imidazopyranotacrines were able to reduce the amount of peroxyl radical, with ORAC values
ranging from 1.35 (9) to 2.75 (10). The most potent antioxidant agent was 10 (2.75), followed by 6 (2.34),
11 (2.33), 4 (2.31) and 13 (2.25). Although it was clear that the naphthol derivatives, and particularly
the 1-naphthol derivatives 10 and 13, were very potent, we observed that compounds 6 and 4, bearing
a fused 3,3-dimethylcyclohexan-1-one, or an acetyl and a methyl groups at C3 and C2, respectively, in
the 4H-pyran core, also showed high antioxidant power. Note also that tacrine has a very low ORAC
value (0.20 ˘ 0.04) [28] compared with most of our synthetic imidazopyranotacrines.
Next, and on the basis of the AChE inhibition and ORAC values, imidazopyranotacrines 2, 4, 8 and
10 were evaluated for their potential hepatotoxicity, since tacrine was withdrawn from the market
because of its liver toxicity.
2.2.3. Hepatotoxicity Analysis on HepG2 Cells
Drug-induced hepatotoxicity is one of the major reasons for drug [31] withdrawal from the
clinic [15], as it happened to tacrine. HepG2 cell is a well-known in vitro system to screen the
hepatotoxicity activity [32]. As shown in Table 2, tacrine was safe up to 100 µM, but significantly
decreased cell viability at 300 µM and at higher concentrations. Among the selected derivatives,
compounds 10 and 8 were more toxic than tacrine (significant reduction of cell viability at 30 and
100 µM), imidazopyranotacrines 2 and 4 resulted significantly less hepatotoxic than tacrine, and very
interestingly, were safe even at 300 µM. Imidazopyranotacrine 4 showed the best safety profile, and
proved to be non-toxic even at the highest tested concentration, namely 1000 µM, with a recorded cell
viability value not significantly different from the control (not significant by the ANOVA test).
Table 2. In vitro toxicity of imidazopyranotacrines, and tacrine in HepG2 cells.
Compounds 1 µM 3 µM 10 µM 30 µM 100 µM 300 µM 1000 µM
Tacrine 95.8 ˘ 2.2 100.4 ˘ 2.2 96.9 ˘ 3.9 97.7 ˘ 3.9 98.6 ˘ 3.8 39.2 ˘ 4.7 *** 20.0 ˘ 2.1 ***
10 101.8 ˘ 4.2 100.7 ˘ 2.6 100.5 ˘ 1.9 71.4 ˘ 7.4 * 63.5 ˘ 6.2 * 64.8 ˘ 5.7 * 66.8 ˘ 4.1 *
8 108.1 ˘ 5.4 101.3 ˘ 10.8 79.0 ˘ 9.1 57.6 ˘ 4.2 ** 52.7 ˘ 3.3 ** 51.2 ˘ 2.8 ** 66.2 ˘ 6.8 *
2 102.7 ˘ 3.7 103.2 ˘ 4.4 101.3 ˘ 3.9 99.2 ˘ 2.6 93.0 ˘ 4.7 87.5 ˘ 3.2 58.8 ˘ 2.1 *
4 107.7 ˘ 5.1 105.3 ˘ 2.9 102.1 ˘ 2.9 98.0 ˘ 3.1 104.6 ˘ 4.5 97.1 ˘ 3.0 96.8 ˘ 1.5
Cell viability was measured as MTT reduction and data were normalized as % control. Data are expressed as
the mean ˘ S.E.M. of triplicate of at least three different cultures. All compounds were assayed at increasing
concentrations (1–1000 µM). *** p ď 0.001, ** p ď 0.01, * p ď 0.05, with respect to control group. Comparisons
between tested compounds and control group were performed by one-way ANOVA.
3. Materials and Methods
3.1. General Information
Melting points were determined on a Kofler apparatus, and are uncorrected. IR spectra were
recorded on a Shimadzu FT-IR 8201 PC spectrophotometer (Shimadzu, Kyoto, Japan), and only
significant absorption bands are reported. 1H-NMR and 13C-NMR spectra were recorded on a
Bruker Avance DPX250 (Bruker Avance DPX250, Bruker BioSpin, Fällanden, Switzerland) or VARIAN
Mercury-300 (Palo Alto, CA, USA) spectrometers at 250 or 300 MHz and at 62 or 75 MHz, respectively
in CDCl3, DMSO-d6 or CD3CN at 250 or 300 MHz and at 62 or 75 MHz, respectively, using solvent
peaks as internal reference. Elemental analyses were performed on a Carlo-Erba CHNS apparatus, at
CNQO (Madrid, Spain). TLC were performed on precoated Merck (Kenilworth, NJ, USA) silica gel
aluminum sheets 60 F254 and detection by UV light at 254 nm or by charring with either ninhydrin,
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anisaldehyde or phosphomolybdic-H2SO4 reagents. Anhydrous solvents were used in all experiments.
Flash column chromatography was performed on silica gel 60 (230 mesh). Commercial grade reagents
were used as supplied from Acros (Geel, Belgium) or Aldrich (Saint Louis, MO, USA).
3.2. General Procedure for the Preparation of 1-Methylimidazole-4H-pyran Derivatives
To a solution of the 2-(1-methyl-1H-imidazol-2-yl)methylene)malononitrile (15) in ethanol
(1 mmol/10 mL), the corresponding 1,3-dicarbonyle (1.1 mmol), and some drops of piperidine were
added. The mixture was stirred at room temperature (rt) and the reaction was monitored by TLC. The
precipitated solid was isolated by filtration, washed with cold ethanol, and purified by silica gel flash
chromatography using AcOEt/Hexane (1:1) as eluent to give pure compounds.
3.3. General Procedure for the Preparation of 1-Methylimidazole-4H-pyran Derivatives from 1- or 2-Naphthol
A mixture of 1 mmol of 2-((1-methyl-1H-(benz)imidazol-2-yl) methylene)malononitrile and 1- or
2-naphthol (1 mmol) in ethanol (10 mL) containing 2–3 drops of piperidine was heated under reflux
for overnight. The reaction mixture was cooled and the precipitated product filtered, washed with
cold ethanol and purified by silica gel flash chromatography using AcOEt or acetone as eluent to give
pure compounds.
3.4. General Method for the Friedländer Reaction
Aluminum chloride (1.5 equiv) was suspended in dry 1,2-dichloroethane at rt. Then, the 4H-pyran
(1 equiv) and the selected cycloalcanone (1.5 equiv) were added, and the reaction mixture was heated at
reflux for 24 h. When the reaction was over (thin layer chromatography analysis), an aqueous solution
of sodium hydroxide (10%) was added dropwise to the mixture until the aqueous solution became
basic. After stirring for 30 min, the precipitate was filtered off and washed with water. The resultant
solid was purified by silica gel flash chromatography using AcOEt as eluent to give pure compounds.
2-(1-Methyl-1H-imidazol-2yl)methylene)malononitrile (15). To a solution of 1-methyl-1H-imidazole-2-
carbaldehyde (14) in ethanol (1.1 g, 10 mmol), 1 equiv (1.58 g, 10 mmol) of malononitrile and 2–3 drops
of piperidine were added, and the mixture was stirred at rt overnight. The precipitated product was
filtered off and washed with cold ethanol to afford 1.47 g (9.3 mmol) of 2-(1-methyl-1H-imidazol-2-yl)
methylene)malononitrile (15) (93% yield): mp 200–202 ˝C; IR (KBr) max 2210 (CN) cm´1; 1H-NMR
(250 MHz, DMSO-d6) δ 8.15 (s, 1H), 7.58 (s, 1H), 7.40 (s, 1H), 3.79 (s, 3H); 13C-NMR (62.9 MHz, CD3CN)
δ 142.7, 141.1, 134.0, 129.2, 115.8, 114.1, 79.3, 34.1. Anal. Calcd. for C8H6N4: C, 60.75; H, 3.82; N, 35.42.
Found: C, 60.50; H, 4.03; N, 35.61.
Ethyl 6-amino-5-cyano-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-4H-pyran-3-carboxylate (16). According
to the general procedure, 2-(1-methyl-1H-imidazol-2-yl)methylene)malononitrile (15) (160 mg, 1.01 mmol),
ethyl acetoacetate (150 mg, 1.15 mmol), and piperidine (2-3 drops), gave 270 mg (0.93 mmol) of the title
compound 16 (93% yield): mp 230 ˝C; IR (KBr) max 3390 (NH2), 2318 (CN), 1689 (CO) cm´1; 1H-NMR
(300 MHz, DMSO-d6) δ 6.96–6.94 (m, 3H), 6.69 (s, 1H), 4.59 (s, 1H), 3.99–3.87 (m, 2H), 3.65 (s, 3H), 2.30
(s, 3H), 0.97 (t, J = 7.1Hz, 3H); 13C-NMR (74.5 MHz, DMSO-d6) δ 165.2, 158.7, 157.6, 149.6, 126.6, 120.7,
119.8, 105.0, 60.0, 54.5, 32.1, 30.1, 18.2, 13.8. Anal. Calcd. for C14H16N4O3: C, 58.32; H, 5.59; N, 19.43.
Found: C, 58.09; H, 5.49; N, 19.32.
5 -Acetyl-2-amino-6-methyl-4-(1-methyl-1H-imidazol-2-yl)-4H-pyran-3-carbonitrile (17). In the same manner,
2-(1-methyl-1H-imidazol-2-yl)methylene)malononitrile (15) (160 mg, 1.01 mmol), 2,4-pentadione (115
mg, 1.15 mmol), and piperidine (2–3 drops), gave 230 mg (0.89 mmol) of the title compound 17 (90%
yield): mp 220 ˝C; IR (KBr) max 3394 (NH2), 2218 (CN), 1616 (CO) cm´1; 1H-NMR (300 MHz, DMSO-d6)
δ 7.00–6.96 (s, 3H), 6.71 (s, 1H), 4.76 (s, 1H), 3.66 (s, 3H), 2.32 (s, 3H), 2.01 (s, 3H) ; 13C-NMR (74.5 MHz,
DMSO-d6) δ 197.5, 159.0, 155.9, 148.8, 126.7, 121.6, 119.9, 113.2, 54.2, 32.3, 30.9, 29.6, 18.8. Anal. Calcd.
for C13H14N4O2: C, 60.45; H, 5.46; N, 21.69. Found: C, 60.23; H, 5.42; N, 21.55.
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2-Amino-7,7-dimethyl-4-(1-methyl-1H-imidazol-2-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile
(18). 2-(1-Methyl-1H-imidazol-2-yl)methylene)malononitrile (15) (160 mg, 1.01 mmol), dimedone
(155 mg, 1.1 mmol) and piperidine (2–3 drops), gave 205 mg (0.69 mmol) of the title compound 18
(69% yield): mp 192–193 ˝C; IR (KBr) max 3367 (NH2), 2183 (CN), 1689 (CO) cm´1; 1H-NMR (300 MHz,
DMSO-d6) δ 7.01 (s, 2H), 6.92 (s, 1H), 6.66 (s, 1H), 4.44 (s, 1H), 3.70 (s, 3H), 2.56–2.03 (m, 4H), 1.03
(s, 3H), 0.99 (s, 3H); 13C-NMR (74.5 MHz, DMSO-d6) δ 196.0, 162.6, 158.9, 149.3, 126.5, 120.6, 119.9,
111.3, 55.5, 49.8, 32.3, 32.1, 25.5, 26.9, 26.5. Anal. Calcd. for C16H18N4O2: C, 64.41; H, 6.08; N, 18.78.
Found: C, 64.50; H, 6.02; N, 18.94.
2-Amino-4-(1-methyl-1H-imidazol-2-yl)-4H-benzo[h]chromene-3-carbonitrile (20). According to the general
procedure, 2-(1-methyl-1H-imidazol-2-yl)methylene)malononitrile (15) (160 mg, 1.01 mmol), 1-naphtol
(146 mg, 1.01 mmol) and piperidine (2–3 drops), gave 228 mg (0.75 mmol) of the title compound 20
(75% yield): mp > 260 ˝C; IR (KBr) max 3433 (NH2), 2376 (CN) cm´1; 1H-NMR (250 MHz, CD3CN) δ
7.95–7.90 (m, 2H), 7.78–7.75 (m, 1H), 7.53–7.43 (m, 2H), 7.30 (d, J = 8.91 Hz, 1H), 7.15 (br,s, 2H), 7.98 (s,
1H), 6.67 (s, 1H), 5.56 (s, 1H), 3.65 (s, 3H); 13C-NMR (62.9 MHz, CD3CN) δ 160.4, 148.9, 146.8, 130.7,
130.6, 129.8, 128.5, 127.3, 126.6, 125.1, 123.2, 121.9, 120.5, 116.8, 113.1, 53.7, 32.4, 31.5. Anal. Calcd. for
C18H14N4O: C, 71.51; H, 4.67; N, 18.53. Found: C, 71.38; H, 4.51; N, 18.46.
2-Amino-1-(1-methyl-1H-imidazol-2-yl)-1H-benzo[f]chromene-3-carbonitrile (19). Following the same
procedure, 2-(1-methyl-1H-imidazol-2-yl)methylene)malononitrile (15) (160 mg, 1.01 mmol), 2-naphtol
(146 mg, 1.01 mmol) and piperidine (2–3 drops), gave 218 mg (0.72 mmol) of the title compound 19
(72% yield): mp > 260 ˝C; IR (KBr) max 3440 .(NH2), 2183 (CN) cm´1; 1H-NMR (250 MHz, DMSO-d6) δ
7.96–7.92 (m, 2H), 7.78–7.75 (m, 1H), 7.51–7.43 (m, 2H), 7.30 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 0.8 Hz, 1H),
6.67 (d, J = 0.9 Hz, 1H), 5.67 (s, 1H), 3.66 (s, 3H); 13C-NMR (62.9 MHz, DMSO-d6) δ 160.4, 148.9, 146.8,
130.7, 130.4, 129.7, 128.5, 127.3, 126.6, 125.0, 123.2, 121.9, 120.5, 116.8, 113.1, 53.7, 32.4, 31.4. Anal. Calcd.
for C18H14N4O: C, 71.51; H, 4.67; N, 18.53. Found: C, 71.47; H, 4.50; N, 18.72.
2-Amino-4-(1-methyl-1H-imidazol-2-yl)-4H-pyrano[3,2-h]quinoline-3-carbonitrile (21). Using the procedure
described above, 2-(1-methyl-1H-imidazol-2-yl) methylene)malononitrile (15) (160 mg, 1.01 mmol),
8-hydroxyquinoline (147 mg, 1.01 mmol) and piperidine (2–3 drops), gave 142 mg (0.47 mmol) of the
title compound 21 (47% yield): mp 244–246 ˝C; IR (KBr) max 3398 (NH2), 2191 (CN) cm´1; 1H-NMR
(250 MHz, CDCl3) δ 8.93–8.91 (m, 1H), 8.22 (dd, J = 8.3 Hz, J = 1.6 Hz, 1H), 7.59–7.51 (m, 2H), 7.12 (d,
J = 8.5 Hz, 1H), 6.90–6.84 (m, 4H), 5.83 (s, 1H), 3.56 (s, 3H); 13C-NMR (62.9 MHz, CDCl3) δ 159.4, 148.9,
146.7, 142.3, 136.5, 134.9, 127.1, 125.7, 124.9, 122.6, 121.3, 120.9, 115.8, 117.1, 52.0, 33.9, 31.7. Anal. Calcd.
for C17H13N5O: C, 67.32; H, 4.32 ; N, 23.09. Found: C, 67.55; H, 4.11; N, 23.25.
Ethyl 5-amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-4,6,7,8-tetrahydrocyclopenta[b]pyrano[3,2-e]pyridine-3-
carboxylate (1). According to the procedure described above, ethyl 6-amino-5-cyano-2-methyl-4-(1-
methyl-1H-imidazol-2-yl)-4H-pyran-3-carboxylate (16) (290 mg, 1.0 mmol), AlCl3 (200 mg, 1.53 mmol),
and cyclopentanone (130 mg, 1.54 mmol), gave 191 mg (0.54 mmol) of the title compound 1 (54%
yield): mp 160–161 ˝C; IR (KBr) max 3344 (NH2); 1704 (CO) cm´1; 1H-NMR (250 MHz, CDCl3) δ 6.85
(s, 1H), 6.66 (s, 1H,), 5.43 (s, 1H
1
), 5.11 (br s, 2H), 4.14–4.02 (m, 2H), 3.42 (s, 3H), 2.87–2.77 (m, 2H),
2.65–2.59 (m, 2H), 2.47 (s, 3H), 2.05–2.02 (m, 2H), 1.14–2.05 (m, 3H); 13C-NMR (62.9 MHz, CDCl3) δ
166.4, 162.4, 161.3, 155.6, 150.1, 147.0, 126.2, 122.6, 118.1, 101.6, 94.5, 60.4, 34.4, 34.3, 32.9, 27.0, 22.1, 19.3,
14.1. Anal. Calcd. for C19H22N4O3: C, 64.39; H, 6.26; N, 15.81. Found: C, 64.16; H, 6.37; N, 15.77.
Ethyl 5-amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-6,7,8,9-tetrahydro-4H-pyrano[2,3-b]quinoline-3-carboxylate
(2). Ethyl 6-amino-5-cyano-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-4H-pyran-3-carboxylate (16)
(300 mg, 1.04 mmol), cyclohexanone (150 mg, 1.53 equiv), and AlCl3 (200 mg, 1.53 mmol), gave 272 mg
(0.74 mmol) of the title compound 2 (72% yield): mp 222–224 ˝C; IR (KBr) max 3343 (NH2); 1701 (CO)
cm´1; 1H-NMR (250 MHz, CDCl3) δ 6.86 (s, 1H), 6.67 (s, 1H), 5.42 (s, 1H), 5.15 (br s, 2H), 4.22–3.99 (m,
2H), 3.43 (s, 3H), 2.70–2.68 (m, 2H), 2.49 (s, 3H), 2.35–2.17 (m, 2H), 1.73–1.15 (m, 4H), 1.13–1.10 (m, 3H);
13C-NMR (62.9 MHz, CDCl3) δ 166.5, 161.4, 154.3, 153.4, 152.1, 147.0, 126.2, 122.6, 113.6, 101.7, 94.3,
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60.5, 34.5, 33.0, 32.5, 22.8, 22.5, 22.3, 19.4, 14.2. Anal. Calcd. for C20H24N4O3: C, 65.20; H, 6.57; N, 15.21.
Found: C, 65.41; H, 6.33; N, 15.02.
Ethyl 5-amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-4,6,7,8,9,10-hexahydrocyclohepta[b]pyrano[3,2-e]pyridine-
3-carboxylate (3). Following the general procedure, ethyl 6-amino-5-cyano-2-methyl-4-(1-methyl-1H-
imidazol-2-yl)-4H-pyran-3-carboxylate (16) (300 mg, 1.04 mmol), AlCl3 (200 mg, 1.53 mmol),
cycloheptanone (170 mg, 1.51 mmol), gave 295 mg (0.77 mmol) of the title compound 3 (74% yield):
mp 196–198 ˝C; IR (KBr) max 3343 (NH2); 1701 (CO) cm´1; 1H-NMR (250 MHz, CDCl3) δ 6.82 (s, 1H),
6.65 (s, 1H), 5.35 (s, 1H), 5.19 (br s, 2H), 4.16–4.01 (m, 2H), 3.40 (s, 3H), 2.81–2.77 (m, 2H,), 2.45–2.40 (m,
5H), 1.79–1.42 (m, 6H,), 1.12–1.14 (m, 3H); 13C-NMR (62.9 MHz, CDCl3) δ 166.3, 161.2, 160.8, 152.9,
151.1, 146.8, 126.1, 122.6, 118.8, 101.7, 95.1, 60.3, 38.5, 34.5, 32.9, 32.0, 29.6, 26.6, 26.0, 25.5, 19.2, 14.1.
Anal. Calcd. for C21H26N4O3: C, 65.95; H, 6.85; N, 14.65. Found: C, 66.01; H, 6.66; N, 14.84.
1-(5-Amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-6,7,8,9-tetrahydro-4H-pyrano[2,3-b]quinolin-3-yl)ethan-1-one
(4). In accordance with the general procedure, 5-acetyl-2-amino-6-methyl-4-(1-methyl-1H-imidazol-2-yl)-
4H-pyran-3-carbonitrile (17) (260 mg, 1.0 mmol), cyclohexanone (150 mg, 1.53 mmol), and AlCl3
(200 mg, 1.53 mmol), gave 175 mg (0.52 mmol) of the title compound 4 (52% yield): mp 243–245 ˝C; IR
(KBr) max 3359 (NH2); 1689 (CO) cm´1; 1H-NMR (250 MHz, CDCl3): δ 6.84 (s, 1H), 6.68 (s, 1H), 5.39 (s,
1H), 5.07 (br s, 2H), 3.37 (s, 3H), 2.65–2.49 (m, 2H), 2.36 (s, 3H), 2.23–2.15 (m, 5H), 1.75–1.67 (m, 4H);
13C-NMR (62.9 MHz, CDCl3) δ 199.1, 159.2, 154.5, 153.2, 151.9, 146.2, 126.3, 123.3, 113.5, 109.4, 93.9,
35.2, 33.0, 32.4, 29.7, 22.7, 22.4, 22.2, 19.6. Anal. Calcd. for C19H22N4O2: C, 67.44; H, 6.55; N, 16.56.
Found: C, 67.31; H, 6.63; N, 16.44.
11-Amino-7,7-dimethyl-10-(1-methyl-1H-imidazol-2-yl)-2,3,6,7,8,10-hexahydrochromeno[2,3-b]cyclopenta[e]
pyridin-9(1H)-one (5). According to the procedure, 2-amino-7,7-dimethyl-4-(1-methyl-1H-imidazol-2-yl)-
5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (18) (300 mg, 1.0 mmol), anhydrous AlCl3
(200 mg, 1.5 mmol) in dry ClCH2CH2Cl (10 mL), and cyclopentanone (130 mg, 1.54 mmol) gave
185 mg (0.51 mmol) of the title compound 5 (51% yield): mp > 260 ˝C; IR (KBr) max 3442 (NH2), 1643
(CO) cm´1; 1H-NMR (250 MHz, CDCl3) δ 6.80 (s, 1H), 6.67 (s, 1H), 5.29 (s, 1H), 4.98 (br s, 2H), 3.41 (s,
3H), 2.60–2.57 (m, 2H), 2.43–2.22 (m, 4H), 2.15–2.06 (m, 2H), 1.96–1.04 (m, 2H), 0.99 (s, 6H); 13C-NMR
(62.9 MHz, CDCl3) δ 196.0, 165.7, 162.0, 155.4, 150.2, 146.7, 126.6, 122.0, 118.4, 109.0, 95.4, 50.5, 41.2,
34.0, 32.7, 31.8, 30.3, 28.3, 28.2, 26.9, 22.0. Anal. Calcd. for C21H24N4O2: C, 69.21; H, 6.64; N, 15.37.
Found: C, 69.01; H, 6.44; N, 15.55.
11-Amino-3,3-dimethyl-12-(1-methyl-1H-imidazol-2-yl)-2,3,4,7,8,9,10,12-octahydro-1H-chromeno[2,3-b]quinolin-
1-one (6). Using the same procedure, 2-amino-7,7-dimethyl-4-(1-methyl-1H-imidazol-2-yl)-5-oxo-5,6,7,8-
tetrahydro-4H-chromene-3-carbonitrile (18) (300 mg, 1.0 mmol), AlCl3 (200 mg, 1.53 mmol), and
cyclohexanone (150 mg, 1.53 mmol), gave 132 mg (0.35 mmol) of the title compound 6 (35% yield):
mp > 260 ˝C; IR (KBr) max 3341 (NH2); 1702 (CO) cm´1; 1H-NMR (250 MHz, CDCl3) δ 6.94 (s, 1H),
6.69 (s, 1H), 5.36 (s, 1H), 4.99 (br s, 2H), 3.49 (s, 3H), 2.75–2.61 (m, 4H), 2.40–2.20 (m, 4H), 1.83–1.31 (m,
4H), 1.14 (s, 6H); 13C-NMR (62.9 MHz, CDCl3) δ 196.3, 166.0, 161.2, 154.4, 152.4, 146.9, 127.1, 122,3,
114,1 109.4, 95.4, 50.8, 41.6, 33.0, 32.5, 32.2, 30.8, 28.6, 22.9, 22.6, 22.4; Anal. Calcd. for C22H26N4O2: C,
69.82; H, 6.92; N, 14.80. Found: C, 69.66; H, 6.78; N, 14.67.
13-(1-Methyl-1H-imidazol-2-yl)-9,10,11,13-tetrahydrobenzo[5,6]chromeno[2,3-b]cyclopenta[e]pyridin-12-amine
(7). In accordance with the general procedure, 2-amino-1-(1-methyl-1H-imidazol-2-yl)-1H-benzo[f ]
chromene-3-carbonitrile (19) (300 mg, 1.0. mmol), AlCl3 (200 mg, 1.53 mmol), cyclopentanone (130 mg,
1.54 mmol), gave 202 mg (0.55 mmol) of the title compound 7 (55% yield): mp > 260 ˝C; IR (KBr) max
3352 (NH2) cm´1; 1H-NMR (250 MHz, CDCl3) δ 8.20 (d, J = 8.4 Hz, 1H), 7.86–7.82 (m, 2H),7.50–7.39
(m, 3H), 6.96 (s, 1H), 6.59 (s, 1H), 6.29 (s, 1H), 5.32 (br s, 2H), 3.08 (s, 3H), 2.99–2.91 (m, 2H), 2.77–2.64
(m, 2H), 2.21–2.09 (m, 2H); 13C-NMR (62.9 MHz, CDCl3) δ 162.8, 156.6, 150.6, 149.5, 147.8, 131.7, 130.8,
130.3, 128.5, 127.5, 126.3, 124.7, 123.5, 123.1, 118.0, 117.6, 110.5, 94.7, 34.8, 34.4, 32.9, 27.3, 22.1. Anal.
Calcd. for C23H20N4O: C, 74.98; H, 5.47; N, 15.21. Found: C, 75.01; H, 5.51; N, 15.02.
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14-(1-Methyl-1H-imidazol-2-yl)-9,11,12,14-tetrahydro-10H-benzo[5,6]chromeno[2,3-b]quinolin-13-amine (8).
Following the general procedure, 2-amino-1-(1-methyl-1H-imidazol-2-yl)-1H-benzo[f ]chromene-3-
carbonitrile (19) (300 mg, 1.0 mmol), AlCl3 (200 mg, 1.53 mmol), and cyclohexanone (150 mg, 1.53
mmol), gave 225 mg (0.59 mmol) of the title compound 8 (59% yield): mp > 260 ˝C; IR (KBr) max 3351
(NH2) cm´1; 1H-NMR (250 MHz, CDCl3) δ 8.20 (d, J = 8.3 Hz, 1H), 7.84–7.80 (m, 2H), 7.52–7.37 (m,
3H), 6.94 (s, 1H), 6.56 (s, 1H), 6.25 (s, 1H), 5.37 (br s, 2H), 3.08 (s, 3H), 2.88–2.72 (m, 2H), 2.44–2.26 (m,
2H), 1.85–1.77 (m, 4H); 13C-NMR (62.9 MHz, CDCl3) δ 154.5, 154.4, 152.6, 149.5, 147.6, 131.7, 130.7,
130.3, 128.5, 127.4, 126.1, 124.6, 123.4, 122.9, 118.0, 112.9, 110.5, 94.4, 34.7, 32.8, 32.6, 22.9, 22.7, 22.5.
Anal. Calcd. for C24H22N4O: C, 75.37; H, 5.80; N, 14.65. Found: C, 75.30; H, 5.82; N, 14.38.
15-(1-Methyl-1H-imidazol-2-yl)-9,10,11,12,13,15-hexahydrobenzo[5,6]chromeno[2,3-b]cyclohepta[e]pyridin-14-
amine (9). Following the general procedure, 2-amino-1-(1-methyl-1H-imidazol-2-yl)-1H-benzo[f ]chromene-
3-carbonitrile (19) 300 mg (1.0. mmol), AlCl3 (200 mg, 1.53 mmol), and cycloheptanone (170 mg, 1.51
mmol), gave 238 mg (0.6 mmol) of the title compound 9 (60% yield): mp > 260 ˝C; IR (KBr) max 3355
(NH2 cm´1); 1H-NMR (250 MHz, CDCl3) δ 8.21 (d, J = 8.2 Hz, 1H), 7.84–7.80 (m, 2H), 7.52–7.37 (m,
3H), 6.95 (s, 1H), 6.57 (s, 1H), 6.32 (s, 1H), 5.43 (br s, 2H), 3.09 (s, 3H), 2.96–2.92 (m, 2H), 2.57–2.53 (m,
2H), 1.87–1.53 (m, 6H); 13C-NMR (62.9 MHz, CDCl3) δ 161.1, 154.1, 151.7, 149.5, 147.6, 131.7, 130.7,
130.3, 128.5, 127.4, 126.2, 124.6, 123.4, 123.0, 118.3, 117.9, 110.6, 95.4, 38.9, 35.0, 32.8, 32.3, 26.9, 26.2, 25.7.
Anal. Calcd. For C25H24N4O: C, 75.73; H, 6.10; N, 14.13. Found: C, 75.66; H, 6.23; N, 14.01.
7-(1-Methyl-1H-imidazol-2-yl)-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amine (10).
Following the general procedure, 2-amino-4-(1-methyl-1H-imidazol-2-yl)-4H-benzo[h]chromene-3-
carbonitrile (20) (300 mg, 1.0 mmol), cyclohexanone (150 mg, 1.53 mmol), and AlCl3 (200 mg,
1.53 mmol), gave 198 mg (0.52 mmol) of the title compound 10 (52% yield): mp > 260 ˝C; IR (KBr) max
3355 (NH2) cm´1; 1H-NMR (250 MHz, CDCl3) δ 8.27 (d, J = 8.3 Hz, 1H), 7.85–7.81 (m, 2H),7.50–7.40
(m, 3H), 6.95 (s, 1H), 6.58 (s, 1H), 6.26 (s, 1H), 5.32 (br s, 2H), 3.09 (s, 3H), 2.81–2.80 (m, 2H), 2.45–2.25
(m, 2H), 1.86–1.78 (m, 4H); 13C-NMR (62.9 MHz, CDCl3) δ 154.6, 154.5, 152.6, 149.5, 147.7, 131.7, 130.7,
130.3, 128.5, 127.5, 126.1, 124.7, 123.5, 122.9, 118.0, 113.0, 110.6, 94.5, 34.8, 32.8, 32.7, 22.9, 22.7, 22.5.
Anal. Calcd. for C24H22N4O: C, 75.37; H, 5.80; N, 14.65. Found: C, 75.12; H, 5.75; N, 14.58.
7-(1-Methyl-1H-imidazol-2-yl)-7,9,10,11,12,13-hexahydrobenzo[7,8]chromeno[2,3-b]cyclohepta[e]pyridin-8-amine
(11). Following the general procedure, 2-amino-4-(1-methyl-1H-imidazol-2-yl)-4H-benzo[h]chromene-3-
carbonitrile (20) (300 mg, 1.0 mmol), cycloheptanone (170 mg, 1.51 mmol), and AlCl3 (200 mg,
1.53 mmol), gave 245 mg (0.62 mmol) of the title compound 11 (62% yield): mp > 260 ˝C; IR (KBr) max
3350 (NH2) cm´1; 1H-NMR (250 MHz, CDCl3) δ 8.21 (d, J = 8.3 Hz, 1H), 7.84–7.80 (m, 2H), 7.51–7.42
(m, 3H), 6.99 (s, 1H), 6.58 (s, 1H), 6.25 (s, 1H), 5.43 (br s, 2H), 3.00 (s, 3H), 2.96–2.92 (m, 2H), 2.57–2.52
(m, 2H), 1.88–1.27 (m, 6H); 13C-NMR (62.9 MHz, CDCl3) δ 161.1, 154.1, 151.7, 149.5, 147.6, 131.6, 130.7,
130.3, 128.5, 127.4, 126.1, 124.7, 123.4, 123.0, 118.3, 117.9, 110.6, 95.3, 38.9, 34.9, 32.8, 32.3, 26.9, 26.5, 25.7.
Anal. Calcd. for C25H24N4O: C, 75.73; H, 6.10; N, 14.13. Found: C, 75.88; H, 6.02; N, 14.25.
7-(1-Methyl-1H-imidazol-2-yl)-7,9,10,11-tetrahydrocyclopenta[51,61]pyrido[31,21:5,6]pyrano[3,2-h]quinolin-8-amine
(12). In accordance with the general procedure, 2-amino-4-(1-methyl-1H-imidazol-2-yl)-4H-pyrano[3,2-h]
quinoline-3-carbonitrile (21) (1.0 mmol, 300 mg), AlCl3 (200 mg, 1.5 mmol) and cyclopentanone
(130 mg, 1.54 mmol), gave 238 mg (0.65 mmol) of title compound 12 (65% yield): mp > 260 ˝C;
IR (KBr) max 3349 (NH2) cm´1; 1H-NMR (250 MHz, CDCl3) δ 9.00–8.98 (m, 1H), 8.11–8.07 (m, 1H),
7.47–7.44 (m, 2H), 7.34–7.23 (m, 1H), 6.94 (s, 1H), 6.71 (s, 1H), 5.89 (s, 1H), 4.92 (br s, 2H), 3.10 (s, 3H),
2.95–2.87 (m, 2H), 2.70–2.59 (m, 2H), 2.15–2.04 (m, 2H); 13C-NMR (62.9 MHz, CDCl3) δ 163.1, 156.7,
150.4, 150.2, 147.8, 146.1, 138.5, 135.6, 128.6, 126.4, 126.3, 123.3, 122.5, 122.1, 117.5, 116.3, 93.5, 36.9, 34.3,
33.0, 27.1, 22.2. Anal. Calcd. for C22H19N5O: C, 71.53; H, 5.18; N, 18.96. Found: C, 71.48; H, 5.33;
N, 19.01.
7-(1-Methyl-1H-imidazol-2-yl)-7,9,10,11,12,13-hexahydrocyclohepta[51,61]pyrido[31,21:5,6]pyrano[3,2-h]quinolin-
8-amine (13). In accordance with the general procedure, 2-amino-4-(1-methyl-1H-imidazol-2-yl)-4H-
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pyrano[3,2-h]quinoline-3-carbonitrile (21) (300 mg, 1.0 mmol), AlCl3 (200 mg, 1.5 mmol), and
cycloheptanone (170 mg, 1.51 mmol), gave 158 mg (0.40 mmol) of title compound 13 (40% yield):
mp 206–207 ˝C; IR (KBr) max 3429 (NH2) cm´1; 1H-NMR (250 MHz, CDCl3) δ 9.00–8.98 (m, 1H),
8.06–8.03 (m, 1H), 7.43–7.36 (m, 2H), 7.28–7.21 (m, 1H), 6.89 (s, 1H), 6.65 (s, 1H), 5.77 (s, 1H), 4.99 (br s,
2H), 3.04 (s, 3H), 2.90–2.76 (m, 2H), 2.63–2.47 (m, 2H), 1.77–1.46 (m, 6H); 13C-NMR (62.9 MHz, CDCl3)
δ 161.5, 153.9, 151.1, 150.3, 147.6, 145.9, 138.3, 135.5, 128.4, 126.4, 126.3, 123.2, 122.3, 122.0, 118.1, 116.4,
94.2, 38.4, 37.1, 32.8, 32.1, 26.8, 26.1, 25.5. Anal. Calcd. for C24H23N5O: C, 72.52; H, 5.83; N, 17.62.
Found: C, 72.67; H, 5.85; N, 17.41.
3.5. In Vitro Toxicity in HepG2 Cells
3.5.1. Cell Culture and Treatment
The human hepatoma HepG2 line cells were purchased from American Type Culture Collection.
The cells were cultured in Eagle’s Minimum Essential Medium (Ozyme, Montigny-le-Bretonneux,
France) supplemented with 10% fetal bovine serum, 1X non-essential amino acids, 100 units/mL
penicillin and 10 mg/mL streptomycin (Dutscher, Brumath, France). Cultures were kept under a
CO2/air (5%/95%) humidified atmosphere at 37 ˝C. Prior to the experiment, cells were seeded in
96-well culture plates at a density of 0.1 ˆ 106 cells per well. After 24 h of incubation, the culture
medium was refreshed and 100 µL of the test compounds or DMSO (0.1%) were added. Compounds
were tested at 7 concentrations (1–1000 µM) in triplicate.
3.5.2. Measurement of Cell Viability
Cell viability, measured as the mitochondrial activity of living cells, was determined by
quantitative colorimetric assay with 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide
(MTT) [33]. Briefly, after 24 h of treatment, cells were incubated with 50 µL MTT (0.5 mg/mL, Sigma
Aldrich) at 37 ˝C for 2 h. Plates were centrifuged, MTT was removed and 100 µL DMSO was distributed
per well. The absorbance was read at 570 nm by microplate spectrophotometry. Cell viability was
expressed as percentage over controls (DMSO, 0.1%).
3.6. Measurement of the Inhibitory Potency against EeAChE
The inhibitory activity on AChE from Electrophorus electricus (type VI-S, Sigma, Milan, Italy),
was evaluated spectrophotometrically by the method of Ellman et al. [27]. AChE stock solution was
prepared by dissolving EeAChE lyophilized powder (Sigma) in 0.1 M phosphate buffer (pH = 8.0)
containing 0.1% Triton X-100. Stock solutions of the tested compounds (1 mM) were prepared in
MeOH/H2O 50/50 (v/v) and diluted in MeOH/H2O 50/50 (v/v). Five increasing concentrations
of each inhibitor were used, able to give an inhibition of the enzymatic activity in the range of
20–80%. The assay solution consisted of a 0.1 M phosphate buffer pH 8.0, with the addition of 340 µM
5,51-dithio-bis(2-nitrobenzoic acid), 0.02 unit/mL of EeAChE and 550 µM of substrate (acetylthiocholine
iodide, ATCh). Assay solutions with and without inhibitor were preincubated at 37 ˝C for 20 min
followed by the addition of substrate. Blank solutions containing all components except EeAChE were
prepared in parallel to account for the non-enzymatic hydrolysis of the substrate. Initial rate assays
were performed at 37 ˝C with a Jasco V-530 double beam spectrophotometer. The rate of increase in
the absorbance at 412 nm was followed for 210 s. The velocity in the presence and absence of inhibitor
were compared and % inhibition was calculated. The results were plotted by placing the percentage of
inhibition in function of the decimal log of the final inhibitor concentration. Linear regression and IC50
values were calculated using Microcal Origin 3.5 software (Microcal Software, Kiev, Ukraine).
3.7. Measurement of the Inhibitory Potency against eqBuChE
The % inhibitory activity on BuChE from horse serum (lyophilized powder, Sigma-Aldrich), was
evaluated spectrophotometrically by the method of Ellman et al. [27]. BuChE stock solutions were
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first dissolved in 0.1 M phosphate buffer (pH 8.0) and then aliquoted in small vials. Compounds
were dissolved in DMSO at 10 mM. The reaction was carried out in a final volume of 3 mL of a
0.1 M phosphate-buffered solution at pH 8.0, containing 5,51-dithiobis-2-nitrobenzoic acid (DTNB,
2625 µL, 0.35 mM, final concentration), eqBuChE (60 µL, 0.05 U/mL final concentration), tested
compound (3 µL, 10 µM, final concentration) and 1% w/v Bovine Serum Albumin phosphate-buffered
(pH 8.0) solution (BSA, 40 µL). The inhibition with respect to control without compound was
determined by pre-incubating this mixture at rt with each compound for 10 min. After this period,
butyrylthiocholine iodide (150 µL, 0.5 mM final concentration) was added and incubated for 15 min at
rt. Then the absorbances were measured at 412 nm in a spectrophotometer plate reader (iEMS Reader
MF, Labsystems). % inhibition given by each compound was calculated and data are expressed as
mean ˘ SEM of at least three different experiments.
3.8. Kinetic Analysis of the Inhibition of EeAChE by Compound 8
To obtain estimates of the inhibition mechanism, reciprocal plots of 1/v vs. 1/[S] were constructed
at different concentrations of the substrate acetylthiocholine (0.111–0.557 mM) by using Ellman1s
method [27] and EeAChE (type VI-S, Sigma). Four concentrations of inhibitor were selected for this
study: 0.850, 2.124, 3.399, 6.798 µM. The plots were assessed by a weighted least-squares analysis
that assumed the variance of the velocity (v) to be a constant percentage of v for the entire data set.
Data analysis was performed with GraphPad Prism 4.03 software (GraphPad Software Inc., San Diego,
CA, USA). The determination of the non-competitive inhibition constant Ki value was carried out
using Dixon plot, i.e., plotting the apparent 1/v vs. inhibitor concentration [I] [34] and confirmed by
Cornish-Bowden plot ([substrate]/v vs. [I]) [28].
3.9. Oxygen Radical Absorbance Capacity Assay
The radical scavenging activity of imidazopyranotacrines 1–13 was determined by the ORAC-FL
method [29,30] using a Varioskan Flash plate reader with built-in injectors (Thermo Scientific). Trolox,
2,21-azobis(amidinopropane) dihydrochloride (AAPH) and fluorescein (FL) were purchased from
Sigma-Aldrich. The reaction was performed at 37 ˝C in 75 mM phosphate buffer (pH = 7.4), and
the final volume reaction mixture was 200 µL. The final concentrations were 1–8 µM for Trolox and
0.1–1 µM for the tested compounds. Briefly, in a black 96-well microplate (Nunc), antioxidant (20 µL)
and fluorescein (120 µL) were incubated for 15 min at 37 ˝C. Then, 2,21-azobis(amidinopropane)
dihydrochloride (60 µL) was added using the built-in injector. The fluorescence at λem 535 nm
(λexc = 485 nm) was measured each minute during 60 min. All assays were made in triplicate and at
least three different assays were performed for each sample. Antioxidant curves were first normalized
to the curve of the blank and then, the area under the fluorescence decay curve (AUC) was calculated as:
AUC “ 1 ` sumpfi{f0q (1)
where f 0 is the initial fluorescence reading at 0 min and fi is the fluorescence value at time i.
The net AUC corresponding to a sample was calculated as follows:
Net AUC “ AUCantioxidant´AUCblank (2)
Regression equations were calculated by plotting the net AUC against the antioxidant
concentration. The ORAC value was obtained by dividing the slope of the latter curve by the slope
of the Trolox curve obtained in the same assay. ORAC values was expressed as µmol of Trolox
equivalent/µmol of imidazopyranotacrines. Data are expressed as mean ˘ SD.
Molecules 2016, 21, 400 13 of 16
4. Conclusions
Although the etiology of AD is a matter of debate, a number of biological targets [35] such
as inhibition of Aβ oligomerization and deposition in senile plaques, halting neurofibrillary tangle
formation, and inhibition of γ- and β-secretase [36] have been identified and exploited to design
new therapies. However, the recent failure in clinical phase III of semagacestat [37], γ-secretase
inhibitor, as well as the clinical phases discontinuation of tideglusib [38], a GSK-3 inhibitor targeting
tau protein, clearly show that the soundest hypotheses for AD have not yet provided any drug for
AD patients cure. Thus, this may be the moment to repurpose old strategies such as the search for
non-hepatotoxic tacrines.
In this context, in this article we have reported our most recent endeavors on this topic [19],
describing a number of imidazopyranotacrines, a new type of tacrine analogues [39–43], as modest and
selective EeAChE inhibitors showing good antioxidant power. Particularly attractive in this family of
compounds is the imidazopyranotacrine 4, which is a modest AChEI, but a potent antioxidant agent,
endowed with a very interesting safety profile on HepG2 cells, i.e., showing lack of hepatotoxicity even
at very high concentration (1000 µM). Other tacrine analogues such as 8 and 10 are significantly more
potent AChEIs than 4 and show good antioxidant power, but also, unfortunately, higher hepatotoxicity,
although compare favorably with tacrine especially at high concentrations (ě 300 µM). Kinetic analysis
showed that compound 8 is a non-competitive AChEI, a mechanism that we have confirmed by
computational chemistry by performing the docking analysis of both enantiomers of compound 8
on AChE. In addition, modeling results showed that the best binding positions for compound 8 on
BuChE were clustered rather far from the active site, at the top of the gorge, explaining thus why this
compound is a poor eqBuChE inhibitor (Supplementary Materials).
We have also calculated the Admission, Distribution, Metabolism, Excretion (ADME) properties
of some selected imidazopyranotacrines. Thus, about 45 physically significant descriptors and
pharmacologically relevant properties of both enantiomers of compounds 2, 4, 8 and 10 were predicted
and some of the important properties were analyzed. All compounds showed significant values for the
properties analyzed and showed drug-like characteristics based on Lipinski1s rule of five (see Table S1,
Supplementary Materials). Drugs currently used for neurological disorders treatment are generally
CNS acting drugs, which show values of MW, Hydrogen Bond (HB) donor, acceptors and rotatable
bonds, etc., in general, in a smaller range than non-CNS therapeutics. Thus, factors that are relevant to
the success of CNS drugs were analyzed. CNS drugs show values of MW < 450, HB donor < 3, HB
acceptors < 7, QPlogPo/w < 5, PSA < 90, number of rotatable bonds < 8 and hydrogen bonds < 8. Thus,
the enantiomers of compounds 2, 4, 8 and 10 satisfied all the characteristic of CNS acting drugs. The
solubility of organic molecules in water has a significant impact on many ADME-related properties.
These compounds present solubility values within the limits. The partition coefficient (QPlogPo/w),
critical for estimation of absorption within the body, ranged between 2.82 and 4.75. The percentage
human oral absorption for the compounds is high, 100%. The most used parameter for Blood Brain
(BB) barrier penetration is log BB. The log BB of many prescribed CNS drugs is >´0.5 and compounds
with log BB <´1.0 penetrate poorly into the brain, yet some commercial CNS drugs have log BB <´1.0.
For compounds 2, 4, 8 and 10, these values lie within the indicated limits of ´3 < QPlogBB < 1.2.
In conclusion, some imidazopyranotacrine derivatives showing selective modest AChE inhibition,
whose pharmacokinetic parameters are within the acceptable range defined for human use, thereby
indicating their potential as drug-like molecules and possible brain penetration, have been discovered
for the potential treatment of AD.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
4/400/s1.
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